BDNF Val66Met polymorphism and brain volumes in multiple sclerosis

Brain derived neurotrophic factor (BDNF) regulates several CNS physiological and pathological processes. To investigate in multiple sclerosis (MS) patients, the relationship between the Val66Met polymorphism of BDNF and clinical markers of disease activity and MRI markers of focal and diffuse brain...

Full description

Saved in:
Bibliographic Details
Published in:Neurological sciences 2011-02, Vol.32 (1), p.117-123
Main Authors: Dinacci, D., Tessitore, A., Russo, A., De Bonis, M. L., Lavorgna, L., Picconi, O., Sacco, R., Bonavita, S., Gallo, A., Servillo, G., Marcuccio, L., Comerci, M., Galletti, P., Alfano, B., Tedeschi, G.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Analysis of Variance
Brain - pathology
Brain-Derived Neurotrophic Factor - genetics
Case-Control Studies
Disability Evaluation
DNA Mutational Analysis
Female
Gene Frequency
Genotype
Humans
Image Processing, Computer-Assisted
Magnetic Resonance Imaging
Male
Medicine
Medicine & Public Health
Methionine - genetics
Middle Aged
Multiple Sclerosis - genetics
Multiple Sclerosis - pathology
Neurology
Neuroradiology
Neurosciences
Neurosurgery
Original Article
Polymorphism, Single Nucleotide - genetics
Psychiatry
Regression Analysis
Valine - genetics
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Brain derived neurotrophic factor (BDNF) regulates several CNS physiological and pathological processes. To investigate in multiple sclerosis (MS) patients, the relationship between the Val66Met polymorphism of BDNF and clinical markers of disease activity and MRI markers of focal and diffuse brain pathologies. 45 MS patients and 34 healthy controls (HCs) were genotyped and subjected to clinical-MRI examination. Global white matter fraction (gWM-f), gray matter-f (GM-f), cerebrospinal fluid-f (CSF-f), and abnormal WM-f were measured. We studied 26 Val/Val and 19 Val/Met patients and 23 Val/Val and 11 Val/Met HCs. We found that Val/Val patients had lower GM-f and higher CSF-f than Val/Val HCs; such differences were not statistically significant comparing Val/Met patients to HCs. The regression analysis showed that both Val/Met genotype and relapse number were associated with lower CSF-f. Our data suggest that Met allele might be a protective factor against MS as it is associated to a lower brain atrophy.
ISSN:1590-1874
1590-3478
DOI:10.1007/s10072-010-0433-z